

Public Health Key Documents: January 2022

## NIHR

### **Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study**

Current literature comparing the interventions for chronic thoracic aortic aneurysms is dated and of limited quality, but both are successful for carefully selected patients although timing of the intervention remains challenging.

Systematic search: Yes

January 2022

<https://www.journalslibrary.nihr.ac.uk/hta/ABUT7744/>

### **Shock-absorbing flooring for fall-related injury prevention in older adults and staff in hospitals and care homes: the SAFEST systematic review**

Evidence around safety of flooring is generally of low quality and much uncertainty remains.

Systematic search: Yes

January 2022

<https://www.journalslibrary.nihr.ac.uk/hta/ZOWL2323/>

### **Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework**

The potential for heterogeneity in treatment effects, in a range of model inputs, across either tumour histologies or other characteristics, is likely to be an important issue for NICE appraisals of histology-independent technologies.

Systematic search: Yes

January 2022

<https://www.journalslibrary.nihr.ac.uk/hta/hta25760/>

## The King's Fund

### **The Covid-19 vaccination programme: trials, tribulations and successes**

Based on interviews with a wide range of people involved in the programme, this report sets out what the roll-out in England has achieved as well as its trials and tribulations. It takes its cut-off point as end of November 2021 (with a brief update to reflect the changed situation due to the Omicron variant).

Systematic search: No

January 2022

<https://www.kingsfund.org.uk/publications/covid-19-vaccination-programme>

## Scottish Medicines Consortium (SMC Advice)

### **eculizumab 300mg (Soliris®)**

NOT recommended for use for the treatment of adults with neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease.

Systematic search: No

January 2022

<https://www.scottishmedicines.org.uk/medicines-advice/eculizumab-soliris-non-sub-smc2456/>

### **opicapone (Ongentys®)**

Accepted for use as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Systematic search: No

January 2022

<https://www.scottishmedicines.org.uk/medicines-advice/opicapone-ongentys-abb-smc2430/>

### **budesonide (Cortiment®)**

Accepted for use for the Induction of remission in patients with active microscopic colitis.

Systematic search: No

January 2022

<https://www.scottishmedicines.org.uk/medicines-advice/budesonide-cortiment-abb-smc2448/>

### **osimertinib (Tagrisso®) is**

Accepted for use as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

Systematic search: No

January 2022

<https://www.scottishmedicines.org.uk/medicines-advice/osimertinib-tagrisso-resub-smc2382/>

### **tralokinumab (Adtralza®)**

Accepted for restricted use for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. Restricted to patients who have had an inadequate response to an existing systemic immunosuppressant or in whom such treatment is considered unsuitable.

Systematic search: No

January 2022

<https://www.scottishmedicines.org.uk/medicines-advice/tralokinumab-adtralza-full-smc2403/>

### **trastuzumab deruxtecan (Enhertu®)**

Accepted for use, on an interim basis subject to ongoing evaluation and future reassessment, as monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received two or more prior anti-HER2-based regimens.

Systematic search: No

January 2022

<https://www.scottishmedicines.org.uk/medicines-advice/trastuzumab-deruxtecan-enhertu-full-smc2388/>

### **tucatinib (Tukysa®)**

Accepted for use in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.

Systematic search: No

January 2022

<https://www.scottishmedicines.org.uk/medicines-advice/tucatinib-tukysa-full-smc2398/>

### **nivolumab (Opdivo®)**

NOT recommended for use in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

Systematic search: No

January 2022

<https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-full-smc2397/>

## **Scottish Government**

### **Coronavirus (COVID-19) volunteering - third sector perspectives: survey report**

Findings from a survey undertaken to gather insights into the experiences of Scottish third sector organisations and other stakeholders involved in supporting volunteering during the pandemic.

Systematic search: No

January 2022

<https://www.gov.scot/publications/scottish-third-sector-perspectives-volunteering-during-covid-19-survey-report/>

### **Women in the justice system: evidence review**

A review of quantitative evidence, drawn from a range of statistical data sources across the justice system in Scotland, comparing findings for women against those for men.

Systematic search: No

January 2022

<https://www.gov.scot/publications/women-justice-system/>

### **Coronavirus (COVID-19): Advisory Sub-Group on Education and Children's Issues - evidence on children, schools, early learning and childcare settings and transmission- summary report**

Summary of evidence on the role of schools in transmission of COVID-19; the risks to children and young people from COVID-19 or from being out of school; workplace-associated risks to staff from COVID-19; and a brief summary of the sub-group's advice to date on how to keep schools open and safe. (Written in August 2021.)

Systematic search: No

January 2022

<https://www.gov.scot/publications/coronavirus-covid-19-evidence-on-children-schools-early-learning-and-childcare-settings-and-transmission-from-covid-19---summary-report/>

### **Ethnicity and justice - academic management: research mapping**

Provides details of previous, current and future research projects around ethnicity and justice from a survey of academics and researchers in Scotland. The survey was carried out on behalf of the Cross Justice Working Group on Race Data and Evidence.

Systematic search: No

January 2022

<https://www.gov.scot/publications/academic-engagement-mapping-previous-current-future-research/>

## **SIGN**

### **SIGN 164: Eating disorders**

This guideline provides recommendations for best practice in the management of people with eating disorders of all ages and gender groups, in any health or social care setting. Eating disorders covered are: anorexia nervosa, bulimia nervosa, binge eating disorder and eating-disordered psychopathology occurring in the context of type 1 diabetes mellitus. It will be of interest to primary,

secondary and tertiary healthcare professionals, education and social care professionals involved in the care of people with eating disorders, as well as patients and their families and carers.

Systematic search: Yes

January 2022

<https://www.sign.ac.uk/our-guidelines/eating-disorders/>

## **Public Health Scotland**

### **COVID-19 Early Years Resilience and Impact Survey (CEYRIS) report: findings from round three (September to October 2021)**

A series of reports covering key behaviours in children, children's play, learning and experience of infection control measures and the experience of parents and carers

Systematic search: No

January 2022

<https://www.publichealthscotland.scot/publications/covid-19-early-years-resilience-and-impact-survey-ceyris-report/covid-19-early-years-resilience-and-impact-survey-ceyris-findings-from-round-three-september-to-october-2021/>

### **Scottish Government target for 20% reduction in car kilometres by 2030: implications for health and health inequalities**

Systematic search: No

January 2022

<https://www.publichealthscotland.scot/publications/scottish-government-target-for-20-reduction-in-car-kilometres-by-2030-implications-for-health-and-health-inequalities>

### **Suicide in Scotland in the COVID-19 pandemic - a comparison of pre-pandemic and pandemic characteristics**

Data for 2020 are compared to 2015-2019 data in order to determine whether the characteristics of individuals who died by suicide during the COVID-19 pandemic differ from the characteristics of individuals who died prior to the pandemic.

Systematic search: No

November 2021

<https://www.publichealthscotland.scot/publications/scottish-suicide-information-database/suicides-in-scotland-in-the-covid-19-pandemic-a-comparison-of-pre-pandemic-and-pandemic-characteristics/>

## **NICE – Guidelines**

### **NG191 COVID-19 rapid guideline: managing COVID-19 (updated)**

Covers the management of COVID-19 for children, young people and adults in all care settings. It brings together existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily.

Systematic review: Limited

Updated January 2022

<https://www.nice.org.uk/guidance/ng191>

### **NG211 Rehabilitation after traumatic injury**

Covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

Systematic search: Yes

January 2022

<https://www.nice.org.uk/guidance/ng211>

## **NICE - Technology Appraisal Guidance**

### **TA761 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection**

Systematic search: Yes

January 2022

<https://www.nice.org.uk/guidance/ta761>

### **TA760 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer**

Systematic search: Yes

January 2022

<https://www.nice.org.uk/guidance/ta760>

### **TA759 Fostamatinib for treating refractory chronic immune thrombocytopenia**

Systematic search: Yes

January 2022

<https://www.nice.org.uk/guidance/ta759>

### **TA757 Cabotegravir with rilpivirine for treating HIV-1**

Systematic search: Yes

January 2022

<https://www.nice.org.uk/guidance/ta757>

### **TA758 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy**

Systematic search: Yes

January 2022

<https://www.nice.org.uk/guidance/ta758>

## **EPPI Centre**

Nil

## **AHRQ (Agency for Healthcare Research and Quality – USA)**

Nil

## **Health Foundation**

### **Tackling the inverse care law**

Analysis of policies to improve general practice in deprived areas since 1990.

Systematic search: No

January 2022

<https://www.health.org.uk/publications/reports/tackling-the-inverse-care-law>

### **Debt and health: preventing ‘problem debt’ during the pandemic recovery**

Key interventions include improving debt collection practices in the public sector and bringing these in line with private sector standards; looking at providing more low-cost credit products; encouraging earlier debt advice before problems grow, and looking at interventions that prevent key

debt triggers – such as the onset of poor health leading to employment loss, or maintaining income when circumstances change.

Systematic search: No

January 2022

<https://www.health.org.uk/publications/long-reads/debt-and-health>

## **Canadian Agency for drugs and Technologies in Health (CADTH)**

### **Nirmatrelvir and Ritonavir (Paxlovid) for Mild to Moderate COVID-19**

Nirmatrelvir and ritonavir are oral medications given in combination to treat Covid-19. Specifically, these medications are used to treat mild to moderate COVID-19 in patients with confirmed SARS-CoV-2 infection who are at high risk for progression to severe COVID-19.

Systematic search: Limited

January 2022

<https://cadth.ca/nirmatrelvir-and-ritonavir-paxlovid-mild-moderate-covid-19>

### **Adalimumab for the Treatment of Adults With Non-Infectious Uveitis**

In the perspective of the health care system in the UK, adalimumab (plus systemic corticosteroid and immunosuppressant therapy) is not more cost-effective than systemic corticosteroid and immunosuppressant use alone (modelled by placebo data) in adults with active and inactive non-infectious uveitis influencing the posterior segment (i.e., back of the eye).

Systematic search: Limited

January 2022

<https://cadth.ca/adalimumab-treatment-adults-non-infectious-uveitis>

### **Orthopedic Footwear for People With Lower-Limb Conditions**

In adults with rheumatoid arthritis, prefabricated orthopedic footwear may reduce foot pain and improve physical functioning, but not affect health-related quality of life. However, this is based on evidence of variable quality from within-group designs, comparing outcomes pre- and postintervention. Due to conflicting results, evidence of variable quality from comparative studies regarding the effectiveness of prefabricated orthopedic footwear for foot pain and foot function in people with inflammation of the soles of the feet (plantar fasciitis) or gout was inconclusive. Evidence of variable quality from 2 systematic reviews suggested that prefabricated orthopedic footwear after a healed diabetic foot ulcer (DFU) may prevent the recurrence of the condition better than conventional shoes at 1 year but not at 2 years. No economic evaluations were identified that evaluated the cost-effectiveness of prefabricated orthopedic footwear for treating people with lower-limb conditions.

Systematic search: Limited

January 2022

<https://cadth.ca/orthopedic-footwear-people-lower-limb-conditions>

### **Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma**

The clinical effectiveness regarding response, relapse, progression-free survival, and overall survival broadly favoured bortezomib-lenalidomide-dexamethasone (RVd) over bortezomib-cyclophosphamide-dexamethasone (CyBorD), although the magnitude and direction of association was not always consistent, and few estimates were statistically significant. Limited evidence on the safety of RVd relative to CyBorD was found. No evidence on the cost-effectiveness of RVd as induction therapy before autologous stem cell transplant for multiple myeloma was found. Among the 5 included guidelines, 3 specifically recommend RVd as a first option for induction therapy

among transplant-eligible newly diagnosed multiple myeloma patients, and 2 recommend more broadly defined 3-drug induction regimens that include RVd.

Systematic search: Limited

January 2022

<https://cadth.ca/lenalidomide-bortezomib-and-dexamethasone-induction-therapy-prior-autologous-stem-cell-transplant>

### **Floatation Therapy for Physical Conditions**

The clinical effectiveness of floatation therapy for the treatment of physical conditions remains uncertain. One randomized controlled trial was identified that evaluated floatation-restricted environmental stimulation therapy (REST) compared with placebo and waitlist control groups for the treatment of patients with chronic pain. The trial reported no significant differences between the 3 treatment groups on any of the outcomes measured including those related to pain, medication use, quality of life, sleep impairment, anxiety, or depression. One guideline was identified that states that there is insufficient evidence to recommend for or against the use of sensory deprivation tanks in patients with symptoms attributed to mild traumatic brain injury.

Systematic search: Limited

January 2022

<https://cadth.ca/floatation-therapy-physical-conditions>

### **Clinical Effectiveness of Opioid Substitution Treatment**

A preponderance of evidence identified in this review indicates a relative benefit in the clinical effectiveness of heroin-assisted treatment, injectable hydromorphone, or diacetylmorphine compared to methadone in patients with opioid use disorder. Most of the evidence in this review describing sustained-release oral morphine versus methadone shows no significant difference in measures of clinical effectiveness for patients with opioid use disorder. There is a lack of evidence reported in systematic reviews and randomized controlled trials describing the clinical effectiveness of oral hydromorphone, fentanyl patches, and fentanyl buccal tablets. Most of the evidence in this review, describing various forms of opioid substitution treatments, has been characterized as low quality and draws from the same several trials.

Systematic search: Limited

January 2022

<https://cadth.ca/clinical-effectiveness-opioid-substitution-treatment>

### **Cost-Effectiveness and Guidelines for Opioid Substitution Treatment**

There was evidence indicating that in the treatment of opioid use disorder, injectable hydromorphone or injectable methadone provided more benefit at less cost compared with injectable diacetylmorphine over a six-month time horizon. Evidence suggests that in the treatment of opioid use disorder, both injectable hydromorphone and injectable diacetylmorphine are likely to provide more benefit at less cost than methadone maintenance treatment. Treatment with injectable hydromorphone was more cost-effective than injectable diacetylmorphine in opioid use disorder patients who do not respond to or relapse from drug treatments. The evidence is limited because observed data was collected during a short-term follow-up, and long-term cost-effectiveness outcomes were based on extrapolations beyond data from the actual studies. One guideline provided a weak recommendation, supported by low-quality evidence, for using slow-release oral morphine in older adults with adequate renal function in whom buprenorphine and methadone maintenance have been ineffective to treat opioid use disorder or could not be tolerated. Another guideline recommends using injectable hydromorphone or injectable diacetylmorphine for individuals with severe opioid use disorders who relapsed previous treatments failed. No relevant cost-effectiveness evidence or guidelines with recommendations regarding the

use of oral hydromorphone, fentanyl patches, or fentanyl buccal tablets for OUD treatment were identified; therefore, no summary can be provided.

Systematic search: Limited

January 2022

<https://cadth.ca/cost-effectiveness-and-guidelines-opioid-substitution-treatment>

**McGill University Health Centre (Canada)**

Nil

**Health Information & Quality Authority (Ireland) – Health Technology Assessments**

Nil

**Campbell Collaboration**

**Parenting interventions to support parent/child attachment and psychosocial adjustment in foster and adoptive parents and children**

Adopted children and children placed in foster care are at increased risk of developing a range of mental health, behavioural and psychosocial adjustment problems. Previous studies suggest that the quality of the attachment between the child and the adoptive/foster parents are important for the child's psychological development. This review finds that attachment-based interventions for adoptive/foster parents increase child psychosocial adjustment and positive parent-child behaviours. For attachment security, parental depressive symptoms, and child internalising and externalising behaviour, the results were inconclusive.

Systematic search: Limited

January 2022

<https://www.campbellcollaboration.org/better-evidence/parenting-interventions-to-support-parent-child-attachment-and-psychosocial-adjustment-in-foster-and-adoptive-parents-and-children.html>

**Glasgow Centre for Population Health**

Nil

**NICE FORWARD PLANNING – Publications due February 2022**

**Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy**

Single Technology Appraisal

**Fostamatinib for treating refractory chronic immune thrombocytopenia**

Single Technology Appraisal

**Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria**

Single Technology Appraisal

**Type 2 diabetes in adults: management (update)**

NICE guideline

**Antimicrobial prescribing: oritavancin for treating acute bacterial skin and skin structure infections in adults**

Antimicrobial prescribing evidence summary

**EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules**



Diagnostics guidance

**Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies**

Technology appraisal guidance

**PredictSURE IBD and IBDX to guide treatment of Crohn's disease**

Diagnostics guidance